ARAV:NSD-Aravive Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 2.79

Change

+0.19 (+7.31)%

Market Cap

USD 0.05B

Volume

0.14M

Avg Analyst Target

USD 18.00 (+545.16%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


Aravive Inc (ARAV) Stock Analysis:
Based on the Aravive Inc stock forecasts from 1 analysts, the average analyst target price for Aravive Inc is USD 18.00 over the next 12 months. Aravive Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Aravive Inc is Slightly Bearish, which is based on 3 positive signals and 5 negative signals. At the last closing, Aravive Inc’s stock price was USD 2.79. Aravive Inc’s stock price has changed by -0.43 % over the past week, -1.16 % over the past month and -57.14 % over the last year.

About

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARAV

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -50.53% 30% F 13% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.53% 30% F 13% F
Trailing 12 Months  
Capital Gain -57.14% 21% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -57.14% 21% F 9% F
Trailing 5 Years  
Capital Gain -96.50% 7% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -96.50% 7% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -2.45% 31% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.45% 31% F 15% F
Risk Return Profile  
Volatility (Standard Deviation) 65.90% 45% F 26% F
Risk Adjusted Return -3.72% 31% F 19% F
Market Capitalization 0.05B 15% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.60 54% F 83% B
Price/Book Ratio 0.98 90% A- 85% B
Price / Cash Flow Ratio -4.36 41% F 65% D
EV/EBITDA 0.25 72% C- 94% A
Management Effectiveness  
Return on Equity -58.32% 50% F 25% F
Return on Invested Capital -42.70% 56% F 19% F
Return on Assets -28.11% 44% F 13% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.31 68% D+ 56% F
Short Percent 1.05% 86% B 72% C-
Beta 2.95 3% F 3% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.